If Race doesn't do a licensing agreement for AML , what would you reckon their strategy would be @IndexInvestor @johndprent
The reason I ask is because @Davisite doesn't seem to be a fan of giving away a lot of the upside and it would be hard to expect BP to put in money for a drug that is still few months away from being clinic ready.
My guess is another SPP but with options thrown in . I am happy to support another SPP depends how attractive it will be for me as well as how detailed the strategy will be.
Why Analysts Believe RAC is “Highly Undervalued”, page-92
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $265.8M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.56 | $1.51 | $95.69K | 62.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3015 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 4018 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |